You are here: Industry Insights > ADHD

News List

Increased Risk for Mortality Seen for Persons With Autism, ADHD drugs.com
February 14, 2022
The risk for mortality is increased significantly for persons with autism spectrum disorders (ASD) and those with attention-deficit/hyperactivity...
Pandemic Especially Tough on Kids With ADHD drugs.com
January 25, 2022
Living through the pandemic has not been easy for kids, but it has really thrown off children who have attention...
Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate AmericanPharmaceuticalReview
December 06, 2021
Noramco, LLC, a leading North American producer of controlled substance bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, today announced it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug...
Exposure to Prenatal Antipsychotics Seems Safe drugs
August 17, 2021
Exposure to prenatal antipsychotics does not appear to be associated with an increased risk for attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), or small for gestational age, according to a study published online Aug. 16.
Drug May Curb 'Sluggish' Thinking drugs
July 02, 2021
Lisdexamfetamine reduces symptoms of sluggish cognitive tempo (SCT) in adults with attention-deficit/hyperactivity disorder (ADHD), according to a study published online June 29 in the Journal of Clinical Psychiatry.
Drug May Curb 'Sluggish' Thinking in Some Adults With ADHD drugs
July 01, 2021
ADHD patients often complain of feeling spacey, slow-moving and lethargic -- symptoms that don't on their face seem to jibe with hyperactivity.
ADHD Meds May Help Keep Some Kids From Thoughts of Suicide drugs
June 09, 2021
ADHD medications might help lessen the risk of suicide in children with serious behavioral issues, a new study suggests.
Tris Pharma® Acquires Park Therapeutics americanpharmaceuticalreview
April 30, 2021
Tris Pharma, Inc., a specialty pharmaceutical company with a portfolio of approved products and a late-stage pipeline of product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related conditions, has acquired Park ...
OWP Pharmaceuticals Announces Patent Application for Treatment of Attention Deficit Hyperactivity Disorder americanpharmaceuticalreview
April 23, 2021
OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.
KemPharm Announces FDA Approval of AZSTARYS for ADHD americanpharmaceuticalreview
March 08, 2021
KemPharm has announced the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for (NDA) AZSTARYS™ (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in ...

Previous page 1 2 3 4 5 6 Next page